Madrigal Pharmaceuticals (MDGL) Cash & Current Investments (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Cash & Current Investments data on file, last reported at $232.2 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $232.2 million, down 72.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $232.2 million (down 72.46% YoY), and the FY2025 annual result was $203.8 million, up 94.05% from the prior year.
• Cash & Current Investments rose to $232.2 million in Q1 2026 per MDGL's latest filing, from $203.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $1.1 billion in Q3 2025 and troughed at $99.9 million in Q4 2023.
• A 5-year average of $488.8 million and a median of $298.4 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2026: Cash & Current Investments jumped 329.79% in 2024, then tumbled 72.46% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $358.8 million in 2022, then slumped by 72.15% to $99.9 million in 2023, then increased by 5.11% to $105.0 million in 2024, then soared by 94.05% to $203.8 million in 2025, then grew by 13.93% to $232.2 million in 2026.
• Business Quant data shows MDGL's Cash & Current Investments at $232.2 million in Q1 2026, $203.8 million in Q4 2025, and $1.1 billion in Q3 2025.